In the second-line treatment of cervical cancer, camrelizumab combined with albumin-bound paclitaxel has been used in a study of recurrent or persistent advanced cervical cancer patients after first-line chemotherapy (NCT05290935). Here, ALB is linked to cervical carcinoma.